Develops cellbased immuno-therapies for the treatment of severe chronic inflammatory diseases|Stephane Boissel, CEO,Txcell 00:10:00
French biotechnology company TxCell, which is developing personalised T-cell immunotherapies for severe chronic inflammatory and autoimmune diseases, has appointed Stéphane Boissel as Chief Executive.Boissel will continue to develop the exclusive worldwide licensing option agreement signed by Ferring and TxCell in December 2013 for the development of TxCell’s lead product Ovasave for the treatment of Inflammatory Bowel Diseases (IBD), including Crohn's disease and ulcerative colitis.
